Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses. - Wikidata - wikimedia - TriplyDB

Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.

Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.

http://www.wikidata.org/entity/Q35683073

about

Sanfilippo syndrome: causes, consequences, and treatments Pathophysiology of heparan sulphate: many diseases, few drugs Newborn screening and diagnosis of mucopolysaccharidoses An integrated approach using orthogonal analytical techniques to characterize heparan sulfate structure Neurodevelopmental Changes in Excitatory Synaptic Structure and Function in the Cerebral Cortex of Sanfilippo Syndrome IIIA Mice Recent advances in cellular glycomic analyses.Glycosaminoglycans detection methods: Applications of mass spectrometry.Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I.Establishment of glycosaminoglycan assays for mucopolysaccharidoses Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB.Heparan sulfate inhibits hematopoietic stem and progenitor cell migration and engraftment in mucopolysaccharidosis I.Identification of chondroitin sulfate linkage region glycopeptides reveals prohormones as a novel class of proteoglycans Amyloidosis, synucleinopathy, and prion encephalopathy in a neuropathic lysosomal storage disease: the CNS-biomarker potential of peripheral blood.Newborn screening for lysosomal storage diseases Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.Arylsulfatase G inactivation causes loss of heparan sulfate 3-O-sulfatase activity and mucopolysaccharidosis in mice.A genetic model of substrate reduction therapy for mucopolysaccharidosis.Diagnosing mucopolysaccharidosis IVA Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates.Glycan-based biomarkers for mucopolysaccharidoses.Lysosomal diseases: diagnostic update.Serum global metabolomics profiling reveals profound metabolic impairments in patients with MPS IIIA and MPS IIIB.Near-Complete Correction of Profound Metabolomic Impairments Corresponding to Functional Benefit in MPS IIIB Mice after IV rAAV9-hNAGLU Gene Delivery.Elevated cerebral spinal fluid biomarkers in children with mucopolysaccharidosis I-H Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B Mice.Site-specific identification of heparan and chondroitin sulfate glycosaminoglycans in hybrid proteoglycans.Neutralizing the anticoagulant activity of ultra-low-molecular-weight heparins using N-acetylglucosamine 6-sulfatase.First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient.Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice.Guanidinylated Neomycin Conjugation Enhances Intranasal Enzyme Replacement in the Brain.Arylsulfatase K is the Lysosomal 2-Sulfoglucuronate Sulfatase.Identification and structural characterization of novel O- and N-glycoforms in the urine of a Schindler disease patient by Orbitrap mass spectrometry.Expanding the chondroitin glycoproteome of Caenorhabditis elegans.Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry.Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses.Fast, sensitive method for trisaccharide biomarker detection in mucopolysaccharidosis type 1.Lysosomal Proteome and Secretome Analysis Identifies Missorted Enzymes and Their Nondegraded Substrates in Mucolipidosis III Mouse Cells

P2860

Q26773200-63E4AA7F-AF21-4357-A8BE-6FFFCC9C5586 Q26823840-0119157C-10A8-48A1-9234-9A53E25D8BFA Q27025080-F3B1EEB7-A0A4-4EE7-A4AA-CF8390E7C665 Q28818221-CA5EAC71-4A3A-41F7-ABAB-95605905B83B Q33572735-A8B3AEC1-894C-4849-BBB7-079B6A186FAD Q33649651-C944A569-1887-40C8-BC64-412CCF6CE1CC Q33816146-B276FAFA-28BA-4AD6-B92A-9647758D5D55 Q34005906-219CF68E-A4C9-440D-B2F5-75D6007757AF Q34318230-A6195486-E222-4E95-A25A-0E9451DBB294 Q34384222-45367AB3-CE18-4FDD-90AA-3F43E2DB8FFC Q34774580-3617348E-4E8F-405B-9DD5-8A2733D788CE Q34884277-546F0A0D-6AD2-4133-B882-31BAE63AE1C1 Q35053456-C574E7CD-251E-46FD-AFBD-F8C468309CDE Q35134207-B2F8A02B-6AB7-4127-A803-D7C0863F832D Q35911463-1A3A20B9-A7DE-415A-B348-65834F783A34 Q36068878-A47D0829-DCA0-478A-B4D4-301F9B8A6D9B Q36332885-34603696-34DD-45C5-8419-43AC63452F2E Q36662855-BE40713D-AA12-43C9-963E-F909EFD09CF9 Q36757021-32F85C46-3073-4385-B5E1-0B6B37D10FE9 Q37161285-989DCFA4-2025-4446-A652-529B4DFC97C6 Q38202920-E9389C20-DB2E-4914-B2EE-7FB6C864D54F Q38851110-5C972397-9B38-455A-AEC0-53D286C514F1 Q38988296-A63A385B-E41C-4F74-A728-389AF4F4AAB9 Q39136670-0D9AF291-933B-41B8-A4EB-E37259659FD8 Q40482507-C477DB53-69D5-46FB-A560-48CE24A9683C Q41267661-C6534B4B-706E-4671-9758-1D977EC5B962 Q41775393-629BB46D-38B7-4828-A993-722B8964AA93 Q42090139-EB3E8E1C-F869-4541-A067-AFB22854FB13 Q43106648-51442776-67DF-4A05-9737-D239ACF5299C Q45931498-4A1D759C-8D7E-4E58-9083-F321E988D471 Q46018872-CFCCEA60-2F0E-4413-A101-8378DE022D75 Q46791866-416DC3CA-2DA7-4190-A40B-95EDE27D9548 Q47402381-CB5BF7C4-1931-496E-99AB-A1FAB843423E Q48484381-59439517-2F6B-447F-9293-896E8879F637 Q54987125-A8951B63-D371-4B76-A4D2-42E7B5B1B13E Q55269135-5E8C1BEF-FC6B-4738-9CFC-15BF838E2D50 Q57529833-538BF9CB-CD50-4A2D-AE58-1A4AEBAA3189

P2860

Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.

http://www.wikidata.org/entity/Q35683073

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.

@ast

Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.

@en

type

label

Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.

@ast

Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.

@en

prefLabel

Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.

@ast

Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.

@en

P1433

Q35683073-A71E0322-2942-4A56-BFCE-FD608CBCDFC0

P1476

Q35683073-A29FCC0B-91C2-4C9D-A54A-446CB0003D5F

P2093

Q35683073-20B0FCE3-9090-42A1-9ECE-1BA7F91DC322

Q35683073-50F16275-B48F-44A1-B6F5-37415892982D

Q35683073-57144C68-ED39-43DC-B051-4B6978A9E4DD

Q35683073-573D1104-6AF6-401B-809E-9D4B0602D233

Q35683073-B72BA154-F602-452C-BD30-C399178C22FA

Q35683073-C2332FCC-16D1-4F35-A97B-4BC4DC7BEC35

Q35683073-CC889154-403F-4412-95F3-F38DB13A3735

P2860

Q35683073-028E9294-7147-4332-9917-F994B719BB1A

Q35683073-03CDB97E-E030-4806-AE04-09A85538AA71

Q35683073-0B80FD6C-5ACE-4200-92B9-79C334EA2B7C

Q35683073-21AA1739-8C4A-4CC7-8EB8-F9A092EFA4B2

Q35683073-2AF3F2C8-1983-40D4-B263-A82EBBAB20C0

Q35683073-3B48832F-20BB-43E0-84D0-FB48E2013BF4

Q35683073-3B95E94C-8379-4296-8DF9-A00469DD71B2

Q35683073-420D8782-C030-4397-AD2D-4B7A77432C22

Q35683073-4F25708E-07A1-4689-894C-7C1B2231352E

Q35683073-4FFE706C-F217-4E83-9063-3F270D027478

P2888

Q35683073-9E793A91-054A-420C-AAA2-2C3BFA49B5A3

P304

Q35683073-A58389A1-72B1-4ABE-8E93-171E9143F98B

P31

Q35683073-66FDBBE7-FDB2-4B5E-8A0B-20D467818138

P356

Q35683073-A90BDB61-C9D3-4FC3-963B-2ECEC6F8B5FA

P433

Q35683073-DE805707-92E1-47F7-B4BC-0246D37C9B6D

P478

Q35683073-FA3B4A58-ADE3-4DC4-886F-77909979CCE4

P50

Q35683073-08F2E57E-9EDE-42AE-9141-F851703974A4

P577

Q35683073-9776C052-46E2-4472-BE9A-546F5816FC92

P5875

Q35683073-3B1594F1-5545-401E-AD2F-E6AE471DB2D8

P698

Q35683073-DC7A1E76-303A-4C43-A835-12EFFDC60D4C

P921

Q35683073-EC14123C-CBED-4423-98F9-F783C7F779A0

P932

Q35683073-BA99ACE4-861F-43CB-A54D-124EE47CBD27

P356

P1433

Nature Chemical Biology

P1476

Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.

@en

P2093

Brett E Crawford

http://www.w3.org/2001/XMLSchema#string

James R Beitel

http://www.w3.org/2001/XMLSchema#string

Jeffrey D Esko

http://www.w3.org/2001/XMLSchema#string

Jillian R Brown

http://www.w3.org/2001/XMLSchema#string

Kanar Al-Mafraji

http://www.w3.org/2001/XMLSchema#string

Roger Lawrence

http://www.w3.org/2001/XMLSchema#string

William C Lamanna

http://www.w3.org/2001/XMLSchema#string

P2860

Glycan reductive isotope labeling for quantitative glycomics

Unraveling the specificity of heparanase utilizing synthetic substrates.

Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis I

Molecular diversity of heparan sulfate.

Secondary storage of dermatan sulfate in Sanfilippo disease.

A comprehensive compositional analysis of heparin/heparan sulfate-derived disaccharides from human serum.

Symbol nomenclature for glycan representation

Mucopolysaccharidosis type I, unique structure of accumulated heparan sulfate and increased N-sulfotransferase activity in mice lacking α-l-iduronidase.

Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis II (Hunter Syndrome).

Sanfilippo disease type D: deficiency of N-acetylglucosamine-6-sulfate sulfatase required for heparan sulfate degradation.

P2888

P304

197-204

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCHEMBIO.766

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Geert-Jan Boons

P577

2012-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221734776

http://www.w3.org/2001/XMLSchema#string

P698

22231271

http://www.w3.org/2001/XMLSchema#string

P921

P932

3262053

http://www.w3.org/2001/XMLSchema#string